Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies
An open-label dose escalation study of T-cell vaccination in multiple sclerosis patients was conducted using attenuated myelin reactive T-cells (MRTC) selected with six myelin peptides, two each from MBP, PLP and MOG. The dose range of subcutaneous injections given at weeks 0, 4, 12 and 20 was 6-9E6...
Description complète
Détails bibliographiques
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 131(2009), 2 vom: 15. Mai, Seite 202-15
|
|---|
| Auteur principal: |
Loftus, B
(Auteur) |
|---|
| Autres auteurs: |
Newsom, B,
Montgomery, M,
Von Gynz-Rekowski, K,
Riser, M,
Inman, S,
Garces, P,
Rill, D,
Zhang, J,
Williams, J C |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | English |
|---|
| Publié: |
2009
|
|---|
| Accès à la collection: | Clinical immunology (Orlando, Fla.)
|
|---|
| Sujets: | Clinical Trial
Journal Article
Immunologic Factors
Myelin Basic Protein
Vaccines
Vaccines, Attenuated
Vaccines, Subunit
tovaxin |
|---|